FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns methods and compositions for improving effectiveness of antibody for medical application with using the compounds potentiating NK-cells. Substance of the invention covers a method of treating a disease and a pharmaceutical composition for treating a disease brought on or exacerbated partially by the cells which can be considered as targets and which can be eliminated by antibody for medical application, involving introduction to a patient of the first antibody blocking an inhibiting NK-cell receptor chosen of group: KIR2DL1, KIR2DL2, KIR2DL3 and NKG2A and then introductions of antibody for medical application.
EFFECT: advantage of the invention consists in higher clinical effectiveness.
40 cl, 2 ex, 1 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NK CYTOLERGY CONTROL COMPOSITIONS AND METHODS | 2004 |
|
RU2404993C2 |
| COMPOSITION AND METHOD FOR CONTROL OF ACTIVITY OF NATURAL KILLER CELLS | 2004 |
|
RU2376315C2 |
| ANTIBODY CAPABLE OF BINDING WITH KIR2DL 1,-2,-3 RECEPTORS BUT NOT WITH KIR2DS4 RECEPTOR AND THERAPEUTIC APPLICATION THEREOF | 2005 |
|
RU2410396C2 |
| SELECTIVE ELIMINATION OF EROSION CELLS | 2012 |
|
RU2617056C2 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| HUMANISED ANTIBODIES WITH INCREASED STABILITY | 2015 |
|
RU2684703C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| ANTI-CANCER TARGETED IMMUNOTHERAPY WITH APPLICATION OF IL-12 | 2015 |
|
RU2689160C2 |
